Our data demonstrate that ASPN is a previously unidentified activator of HER2/HER3 signaling and HER2-dependent migration in prostate cancer cells, thereby supporting a role for this signaling axis in advanced prostate cancer. Here, ASPN is linked to prostate carcinoma.